Clinical Trials

Phase 1 Active not recruiting

Metastatic Castration-sensitive Prostate Cancer

NCT04577833 2026-06-05

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05784012 2026-06-04

RADIAN

34 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05523440 2026-06-03

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Phase 2 Terminated

9 enrolled 10 charts

Ovarian Neoplasms, Endometrial Neoplasms

NCT06412120 2026-06-03

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

Phase 4 Recruiting

70 enrolled

Ovarian Neoplasms

NCT06433219 2026-06-03

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

63 enrolled

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT06915025 2026-06-02

OVATION-3

Phase 3 Recruiting

500 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03651206 2026-06-01

ROCSAN

Phase 2/3 Recruiting

138 enrolled

GynecologicSarcoma

Ovarian Carcinosarcoma

NCT04992013 2026-06-01

Niraparib in Tumors Metastatic to the CNS

20 enrolled

CNS

Neoplasm Metastasis, Central Nervous System Neoplasms

NCT05718323 2026-05-29

RAISE

44 enrolled

Thoracic

SCLC,Extensive Stage

NCT04037254 2026-05-20

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

Phase 1/2 Completed

22 enrolled 13 charts

Prostatic Neoplasms

NCT05615818 2026-05-19

SAFIR-ABC10

Phase 3 Recruiting

800 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT04947254 2026-05-15

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

200 enrolled

Prostatic Neoplasms

NCT04030559 2026-05-14

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Phase 2 Terminated

11 enrolled 7 charts

Prostatic Neoplasms

NCT04584255 2026-05-13

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

62 enrolled

Breast

Breast Neoplasms

NCT03431350 2026-05-11

QUEST

136 enrolled 29 charts

Phase 1 Active not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT04502602 2026-05-11

iNNOVATE

18 enrolled

Ovarian Neoplasms

NCT05689021 2026-05-11

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

8 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04170153 2026-05-07

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

161 enrolled

Neoplasm Metastasis

NCT04313504 2026-05-07

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

Phase 2 Completed

10 enrolled 9 charts

Head & Neck

Head and Neck Neoplasms

NCT05601440 2026-05-07

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

484 enrolled

Breast

Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06212583 2026-05-06

KNIGHTS

88 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT04194554 2026-05-01

ASCLEPIuS

102 enrolled

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04475939 2026-05-01

ZEAL-1L

Phase 3 Completed

666 enrolled 21 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03768063 2026-04-28

IMbrella B

1,000 enrolled

Phase 1/2 Active not recruiting

Neoplasms

NCT06077877 2026-04-24

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

42 enrolled

Neoplasms

NCT04701307 2026-04-22

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

48 enrolled

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT06180356 2026-04-22

ANALLISA

30 enrolled

Ovarian Neoplasms

NCT05183984 2026-04-13

NIRVANA-1

390 enrolled

Ovarian Neoplasms

NCT06392841 2026-04-08

HARMONY

Phase 2 Withdrawn

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT05335993 2026-04-03

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

10 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06388733 2026-04-01

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

Phase 3 Recruiting

450 enrolled

CNS

Brain Neoplasms, Glioblastoma

NCT03601923 2026-03-25

Niraparib in Patients With Pancreatic Cancer

Phase 2 Completed

32 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05198804 2026-03-18

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Phase 1/2 Completed

117 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05694715 2026-03-17

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Phase 1 Recruiting

24 enrolled